2. Guiding principles
Consolidated ARV guidelines, June 2013
2.4 Increasing the effectiveness and efficiency of programmes
In the context of limited financial resources, competing priorities and health system constraints, countries may face difficult choices among an expanding range of options for using ARV drugs to reduce HIV morbidity, mortality and transmission. These guidelines are based on the principle that countries should further scale up and optimize the effectiveness and efficiency of HIV programmes through a strategic approach to using ARV drugs that involves:
- giving priority to providing ARV drugs to people living with HIV who are eligible for treatment and most in need;
- exploring opportunities to enhance the impact of ARV drugs on HIV prevention by starting treatment earlier in certain populations;
- increasing the effectiveness and reach of ARV programmes across the continuum of care through a strategic mix of quality-assured HIV testing approaches, improving adherence and retention, innovative service delivery, integrating ART in a wider range of settings and strengthening links between services; and
- engaging in both short- and longer-term efforts to optimize and harmonize drug regimens and increase their affordability and to develop and implement simpler and more affordable point-of-care diagnostics and laboratory services.